个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共7条记录   FUTURE PERSPECTIVES OF EPIGENETIC DRUGS IN ORAL CANCER [作者：Vogiatzi, P; Claudio, PP,期刊：Drugs of the Future, 页码：201-207 , 文章类型： Review，,卷期：2011年36-3] Oral cancer, predominantly in the form of squamous cell carcinoma, affects 500,000 people worldwide each year and is the most common head and neck cancer. Major risk factors are the use of tobacco and alcohol consumption... HEARING LOSS: WHAT'S IN THE PIPELINE? [作者：Chen, C; Lobarinas, E; Ding, D; Salvi, R,期刊：Drugs of the Future, 页码：209-227 , 文章类型： Review，,卷期：2011年36-3] Hearing loss due to aging, hereditary factors, noise exposure, ototoxic drugs and infection is a major healthcare problem. While the causative agents of hearing loss are diverse, many share common sequelae involving oxid... PROGRESS IN THE DELIVERY OF SIRNA THERAPEUTICS: POTENTIAL IN UVEAL MELANOMA [作者：Gollob, JA; Bumcrot, D; Toudjarska, I; Bastian, BC; Sah, DW; Vaishnaw, AK,期刊：Drugs of the Future, 页码：229-239 , 文章类型： Review，,卷期：2011年36-3] Since 2006, when Fire and Mello were awarded the Nobel Prize in Medicine for their work on RNA interference (RNAi), there has been significant progress towards transforming what began as an important laboratory tool for ... TARGETING HSP 27 FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER [作者：Zoubeidi, A; Chi, KN; Gleave, M,期刊：Drugs of the Future, 页码：241-247 , 文章类型： Article，,卷期：2011年36-3] Prostate cancer is the most common cancer in men and the second leading cause of death from cancer in North America. While responsive to androgen ablation in its early stages, prostate cancer eventually becomes castratio... GANITUMAB Human Anti-CD221 (IGF-IR) Monoclonal Antibody [作者：Cole, P; Suria, R,期刊：Drugs of the Future, 页码：175-181 , 文章类型： Article，,卷期：2011年36-3] Ganitumab (AMG-479) is a fully human monoclonal IgG(1) antibody that binds insulin-like growth factor 1 receptor (ICE-I receptor) and is being evaluated in clinical studies as monotherapy and in combination with other ag... LCZ-696 Angiotensin AT(1) Receptor Antagonist/Neprilysin Inhibitor Treatment of Heart Failure Treatment of Hypertension [作者：Chrysant, SG,期刊：Drugs of the Future, 页码：183-190 , 文章类型： Article，,卷期：2011年36-3] LCZ-696 is an investigational, dual-acting molecule consisting of the angiotensin II (Ang II) type 1 (AT(1)) receptor blocker (ARB) valsartan and the neprilysin (neutral endopeptidase, NEP) inhibitor AHU-377. The rationa... VEMURAFENIB B-raf Kinase Inhibitor Oncolytic [作者：Puzanov, I; Flaherty, KT; Sosman, JA; Grippo, JF; Su, F; Nolop, K; Lee, RJ; Bollag, G,期刊：Drugs of the Future, 页码：191-199 , 文章类型： Article，,卷期：2011年36-3] Vemurafenib (RG-7204, PLX-4032) is a potent inhibitor of the V600E mutation-positive B-raf kinase. Mutations in this protein have been implicated in approximately 50% of melanomas, 30-70% of thyroid tumors, 30% of serous...